Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia

被引：28
|
作者：
Frey, Noelle, V [1 ]
机构：
[1] Hosp Univ Penn, Abramson Canc Ctr, Div Hematol Oncol, Cell Therapy & Transplant, 3400 Spruce St, Philadelphia, PA 19104 USA
来源：
BLOOD | 2022年 / 140卷 / 01期
关键词：
CAR-T-CELLS; B-CELL; YOUNG-ADULTS; THERAPY; CHILDREN;
D O I：
10.1182/blood.2021014892
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In October 2021, brexucabtagene autoleucel became the first anti-CD19 chimeric antigen receptor T-cell product to receive approval from the Food and Drug Administration to treat adults with relapsed and refractory B-cell acute lymphoblastic leukemia. The approval is based on results from the Zuma-3 trial and significantly widens treatment options for this patient population. In this article, we review outcomes from this study and its implications.
引用
收藏
页码：11 / 15
页数：5
相关论文
共 50 条
  • [1] New European approval: Brexucabtagene autoleucel in adult relapsed/refractory acute lymphoblastic leukemia
    Lemoine, Jean
    Marchand, Tony
    BULLETIN DU CANCER, 2022, 109 (12) : 1232 - 1233
  • [2] FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Bouchkouj, Najat
    Lin, Xue
    Wang, Xiaofei
    Przepiorka, Donna
    Xu, Zhenzhen
    Purohit-Sheth, Tejashri
    Theoret, Marc
    ONCOLOGIST, 2022, 27 (10): : 892 - 899
  • [3] The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    O'Connor, Timothy E.
    Lin, Chenyu
    Roloff, Gregory W.
    Zhang, Amy
    Aldoss, Ibrahim
    Faramand, Rawan
    Kopmar, Noam E.
    Dykes, Kaitlyn C.
    Jeyakumar, Nikeshan
    Dekker, Simone E.
    Gupta, Vishal K.
    Ahmed, Mohamed
    Logan, Aaron C.
    Zambrano, Hector
    Bradshaw, Danielle
    Mercadal, Santiago
    Schwartz, Marc
    Tracy, Sean
    Kubiak, Michal
    Mukherjee, Akash
    Majhail, Navneet
    Battiwalla, Minoo
    Mountjoy, Luke
    Malik, Shabaz
    Mathews, John
    Shaughnessy, Paul
    Ladha, Abdullah
    Yaghmour, George
    Advani, Anjali S.
    Stefan, Maryann
    Guzowski, Caitlin
    Hoeg, Rasmus T.
    Hilal, Talal
    Moore, Jozal
    Sasine, Joshua
    Solh, Melhem M.
    Lee, Catherine J.
    Kota, Vamsi K.
    Koura, Divya
    Veeraputhiran, Muthu
    Blunk, Betsy
    Leonard, Jessica T.
    Oliai, Caspian H.
    Bachanova, Veronika
    Stock, Wendy
    Cassaday, Ryan D.
    Shah, Bijal D.
    Miller, Katharine
    Muffly, Lori S.
    Galal, Ahmed
    BLOOD, 2023, 142
  • [4] Agents for refractory/relapsed acute lymphocytic leukemia in adults
    Qian, L. -R.
    Fu, W.
    Shen, J. -L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (17) : 2465 - 2474
  • [5] BREXUCABTAGENE AUTOLEUCEL FOR ADULT PATIENTS WITH REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA: COST-EFFECTIVENESS IN THE CLINICAL SUBSETS
    Marchetti, Monia
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 198 - 198
  • [6] Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
    Kopmar, Noam E.
    Cassaday, Ryan D.
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 1587 - 1596
  • [7] Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
    Mian, Agrima
    Hill, Brian T.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 435 - 441
  • [8] Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
    Muhsen, Ibrahim
    Advani, Anjali S.
    Roloff, Gregory W.
    Jeyakumar, Nikeshan
    Miller, Katharine
    Zhang, Amy
    Sutherland, Katherine C.
    Grunwald, Michael R.
    Kota, Vamsi K.
    Boccucci, Jacob
    Ulrickson, Matthew
    Sasine, Joshua
    Aldoss, Ibrahim
    Othman, Tamer
    Vasu, Sumithira
    Reshef, Ran
    Luskin, Marlise R.
    Chen, Evan C.
    Lin, Chenyu
    Langston, Amelia
    Cassaday, Ryan D.
    Kopmar, Noam E.
    Tsai, Stephanie B.
    O'Connor, Timothy E.
    Hilal, Talal
    Faramand, Rawan
    Park, Jae H.
    Valtis, Yannis K.
    Solh, Melhem M.
    Bezerra, Evandro
    Leonard, Jessica T.
    Dekker, Simone E.
    Majhail, Navneet
    Battiwalla, Minoo
    Malik, Shahbaz A.
    Mathews, John
    Shaughnessy, Paul
    Mountjoy, Luke
    Hoeg, Rasmus T.
    Oliai, Caspian H.
    Gupta, Vishal
    Koura, Divya
    Dykes, Kaitlyn C.
    Logan, Aaron C.
    Kumaran, Muthu, V
    Stock, Wendy
    Schwartz, Marc
    Bachanova, Veronika
    Tracy, Sean
    O'Dwyer, Kristen M.
    BLOOD, 2024, 144 : 523 - 526
  • [9] Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
    Aydilek, Enver
    Klein-Scory, Susanne
    Thomson, Julia
    Nilius-Eliliwi, Verena
    Vangala, Deepak
    Schroers, Roland
    Wulf, Gerald
    Mika, Thomas
    HEMASPHERE, 2023, 7 (09):
  • [10] Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma
    Marchetti, M.
    Visco, C.
    LEUKEMIA & LYMPHOMA, 2023, 64 (08) : 1442 - 1450
12345